The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Advertisement
Advertisement
Trending on OncLive
1
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
2
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
3
Dr Hoffmann on the Significance of Efficacy Data for Sonrotoclax Plus Zanubrutinib in MCL
4
Dr Cooper on Biomarker Selection for DLL3-Targeted Therapies in ES-SCLC
5